Your browser doesn't support javascript.
loading
Evaluating Antibody Pharmacokinetics as Prerequisite for Determining True Efficacy as Shown by Dual Targeting of PD-1 and CD96.
Boch, Christina; Reschke, Markus; Igney, Frederik; Maier, Peter; Müller, Philipp; Danklmaier, Sarah; Das, Krishna; Hofer, Tamara; Wollmann, Guido; Rist, Wolfgang.
Afiliação
  • Boch C; Boehringer Ingelheim Pharma GmbH & Co. KG, 88400 Biberach an der Riss, Germany.
  • Reschke M; Boehringer Ingelheim RCV GmbH & Co. KG, 1120 Vienna, Austria.
  • Igney F; Boehringer Ingelheim Pharma GmbH & Co. KG, 88400 Biberach an der Riss, Germany.
  • Maier P; Boehringer Ingelheim Pharma GmbH & Co. KG, 88400 Biberach an der Riss, Germany.
  • Müller P; Boehringer Ingelheim Pharma GmbH & Co. KG, 88400 Biberach an der Riss, Germany.
  • Danklmaier S; Institute of Virology, Medical University Innsbruck, 6020 Innsbruck, Austria.
  • Das K; Christian Doppler Laboratory for Viral Immunotherapy of Cancer, 6020 Innsbruck, Austria.
  • Hofer T; Institute of Virology, Medical University Innsbruck, 6020 Innsbruck, Austria.
  • Wollmann G; Christian Doppler Laboratory for Viral Immunotherapy of Cancer, 6020 Innsbruck, Austria.
  • Rist W; ViraTherapeutics GmbH, 6063 Rum, Austria.
Biomedicines ; 10(9)2022 Sep 01.
Article em En | MEDLINE | ID: mdl-36140247
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article